SCHEMBL1244675

SCHEMBL1244675

O=C1NC(=S)SC1=Cc1cc(Cc2ccc(Cl)cc2)cs1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 2/20 0.56
▸ NAT1 P18440 2/20 0.56
▸ MAX P61244 2/20 0.56
▸ PTP4A3 O75365 2/20 0.52
▸ CRHBP P24387 2/20 0.52
▸ CRHR2 Q13324 2/20 0.52
▸ DNM1 Q05193 1/20 0.51
▸ PIK3CG P48736 2/20 0.50
▸ ADAMTS5 Q9UNA0 3/20 0.49
▸ PIM1 P11309 6/20 0.49
▸ MTOR P42345 1/20 0.47
▸ RPTOR Q8N122 1/20 0.47
▸ MLST8 Q9BVC4 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ADAMTS4 O75173 1/20 0.45
▸ PLA2G1B P04054 1/20 0.44
▸ ATG4B Q9Y4P1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1244674 1.00 MYC (0.56) MYCNAT1MAXPTP4A3CRHBP
SCHEMBL1243983 0.78 PIM1 (0.55) NAT1PTP4A3PIK3CGADAMTS5PIM1
SCHEMBL1243984 0.78 PIM1 (0.55) NAT1PTP4A3PIK3CGADAMTS5PIM1
SCHEMBL1243980 0.78 PIM1 (0.55) NAT1PTP4A3PIK3CGADAMTS5PIM1
SCHEMBL1249067 0.73 NAT1 (1.00) MYCNAT1MAXCRHBPCRHR2
SCHEMBL1249069 0.73 NAT1 (1.00) MYCNAT1MAXCRHBPCRHR2
SCHEMBL20816059 0.73 NAT1 (1.00) MYCNAT1MAXCRHBPCRHR2
SCHEMBL1242209 0.73 HSD17B10 (0.38) —
SCHEMBL8172015 0.72 MYC (0.61) MYCNAT1MAXPTP4A3CRHBP
SCHEMBL2224453 0.72 NAT1 (0.66) NAT1PTP4A3PIM1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884124-B2 such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions SEPRACOR INC. (US) 2011-02-08 — — US disclosed
EP-2057162-A2 FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE Sepracor Inc. (US) 2009-05-13 — — EP disclosed
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase SEPRACOR INC. (US) 2008-03-06 — — US disclosed
WO-2008005456-A2 FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-01-10 — — WO disclosed
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase DAO, DDO, AOX1 MYC 3400/4885NAT1 481/4885MAX 916/4885
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE DAO, DDO, AOX1 MYC 3145/4885NAT1 694/4885MAX 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback